Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease.
Journal
NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
medline:
1
1
2022
pubmed:
1
1
2022
entrez:
6
2
2024
Statut:
ppublish
Résumé
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease This phase 1b/2a, randomized, double-blind, placebo-controlled, dose-escalation trial tested low-dose subcutaneous aldesleukin (recombinant IL-2) in patients with ischemic heart disease. Low-dose IL-2 expanded Tregs, without adverse events of major concern. Single-cell RNA-sequencing of circulating immune cells was used to provide mechanistic assessment of the treatment's effects.
Identifiants
pubmed: 38319239
doi: 10.1056/EVIDoa2100009
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM